| Patient | Frédéric Chopin |
|---|---|
| Date of birth | 1810-03-01 |
| Identifiers | MRN HR-NI020-SYN-TD; SSN (made up) 000-20-8845 |
| Document date | 1838-05-15 |
| Author | Matthias Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
End of the eight-week intensive phase. [S]
Mr. Chopin completed the 56 doses of the intensive phase yesterday, all observed by video within eight weeks, and pyrazinamide has stopped; from today he takes rifapentine, moxifloxacin, isoniazid, and pyridoxine for nine more weeks. The isolate is susceptible to rifampin, isoniazid, pyrazinamide, and moxifloxacin. The cultures from the third week show no growth at six weeks. His cough has gone except for a little phlegm on waking, and he has gained 3.5 kg since diagnosis. He has no tendon pain, tingling, yellowing, or rash. He is teaching twelve students a week and has told them about his illness; none has left. The health department tells him the investigation of his contacts is going well, without giving him details. [S]
| Element | Detail |
|---|---|
| Treatment | 56 of 56 intensive-phase doses observed; continuation phase from today |
| Susceptibility | Susceptible to rifampin, isoniazid, pyrazinamide, and moxifloxacin |
| Cultures | Third-week cultures negative at six weeks |
| Weight | 52.0 kg, up 3.5 kg |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | A little phlegm on waking; no cough during the day; no blood |
| Constitutional | Negative | No fever or night sweats; appetite good |
| Musculoskeletal | Negative | No tendon pain |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood good; PHQ-9 4; no thoughts of suicide or self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food | 1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses) | Oral route | 1838-03-20 to 1838-07-16 | completed | S |
| Moxifloxacin 400 mg tablet, one tablet daily | 400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours after | Oral route | 1838-03-20 to 1838-07-16 | completed | S |
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeks | Oral route | 1838-03-20 to 1838-07-16 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg) | Oral route | 1838-03-20 to 1838-05-14 | completed | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 1838-03-20 to 1838-07-16 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1838-05-15 | Body height | 170 | cm | S |
| 1838-05-15 | Body weight | 52 | kg | S |
| 1838-05-15 | Body mass index (BMI) [Ratio] | 18 | kg/m2 | S |
| 1838-05-15 | Systolic blood pressure | 108 | mm[Hg] | S |
| 1838-05-15 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1838-05-15 | Heart rate | 78 | /min | S |
| 1838-05-15 | Respiratory rate | 16 | /min | S |
| 1838-05-15 | Body temperature | 36.8 | Cel | S |
| 1838-05-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1838-05-15 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 7-56 U/L | Normal | S |
| 1838-05-15 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 10-40 U/L | Normal | S |
| 1838-05-15 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1838-05-15 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1838-05-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
Vital signs recorded on 1838-05-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 52.0 kg |
| Eyes | No icterus |
| Respiratory | Clear apart from a few fine crackles at the right apex |
| Musculoskeletal | Tendons non-tender |
| Neurological | Normal sensation in the fingers and feet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and culture | resolved | confirmed | R04.2 | S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit. |
| Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | A15.0 | S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic. |
| Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dL | active | confirmed | E44.0 | S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | Every visit | Completed today | Morning phlegm only |
| Examination | Weight, with the pyrazinamide dose checked against the weight band | Monthly | Completed today | 52.0 kg; pyrazinamide finished within its band |
| Medication safety | Adverse effects: hepatitis symptoms, tendon pain, numbness or tingling, rash, nausea, orange body fluids | Every visit | Completed today | None |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; repeat for symptoms or risk factors (here at two to three weeks, for low weight and albumin) | Completed today | ALT 29, AST 27 U/L, bilirubin 0.6 mg/dL, all normal |
| Laboratory | Hemoglobin | When low at baseline | Completed today | 13.0 g/dL, up from 12.1; anemia of inflammation resolving |
| Laboratory | Phenotypic susceptibility (rifampin, isoniazid, pyrazinamide, moxifloxacin) | At baseline | Completed today | Susceptible to rifampin, isoniazid, pyrazinamide, and moxifloxacin |
| Laboratory | Sputum acid-fast smear and culture | Baseline, then monthly until two consecutive cultures are negative | Completed today | Third-week cultures: no growth at six weeks (first negative culture) |
| Laboratory | Two-month sputum culture | At the end of the intensive phase; a positive result needs evaluation and repeat susceptibility testing | Completed today | Smear negative today; culture sent |
| Imaging | Chest X-ray | Baseline; at two months only if baseline cultures were negative; end of treatment optional | Not indicated | Not needed at two months, because the baseline cultures were positive |
| Medication safety | Doses observed and the completion clock (56 doses within 70 days, 63 within 84 days, 119 within five months) | Every visit | Completed today | 56 doses in 56 days, within the 70-day limit |
| Referral | Contact investigation (students, friends, close contacts) | Led by the health department from diagnosis | Referred | Continuing with the health department; no results in his record |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Completed today | 4, item 9 scored 0 |
| Self-management | Nutrition: dietitian, intake, supplement drinks | Every visit until weight is restored | Completed today | Supplements continue; eating well |
| Referral | Infectious diseases review | At diagnosis, at two months, and at the end of treatment | Completed today | Results reviewed by message today |
Goal progress:
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: End-of-treatment visit after the 119th dose. Call the same day for hepatitis symptoms, tendon pain, or a returning cough. Next scheduled visit 1838-07-21: end-of-treatment review after 119 doses. [S]